20 August 2026

A small move back up, and not a reversal of yesterday's cut. Yesterday priced a raised cost of a second contested posture off the FTC primary. Today Hims & Hers shipped a new product line — AI weight-loss care plus a smart scale (simplywall.st, 08-19) — and publicly committed to expanded patient access while rejecting the allegations (Benzinga, 08-19), with the CEO arguing the suit "misses the point of its care model" (Briefs Finance, 08-19). That is the GoodRx / BetterHelp reference class behaving exactly as the Historian said it would: absorb the action, do not pause the roadmap. So the reference class earns a little more weight and the FTC discount a little less. Held to +0.02 deliberately: every item is SECONDARY, two of the three are the defendant's own posture restated by trade press, and a defendant promising expanded access three weeks into a federal complaint is what any defendant says. Against it, day 28 and the Federal Register still shows count 5, none a 503A bulks action — the legal pathway a compliant launch needs has not moved. Skeptic near 0.59, Bayesian 0.66; divergence 0.07, under the flag line.

Confirmation that banks nothing. bestpeptideforthat took 0 clicks across 51 pages in the 28 days to 08-19; its whole strike zone is four queries at four impressions total, and both 7-day reports came back EMPTY. Impressions read 181 yesterday and 133 today as 07-21 rolled out of the window — window roll, not decay, per the 08-17 amendment, and clicks are 0 on both readings. glp1picks took 1,252 clicks on 76,447 impressions, up 15 and 353 day over day. The new fact is that a third property now has measurable clicks — glp1pets, 11 clicks on 1,737 impressions, 5 of them in the last 7 days — and it is not the peptide one.

Third day at ceiling. Today's four items — University of Rochester on GLP-1 microdosing risks (08-19), The Well News on FDA concern over unapproved GLP-1 products (08-19), thefashionlaw.com on Lilly policing its own retatrutide gray market pre-launch (08-19), Genetic Literacy Project on testosterone (08-19) — are the same widening backlash wave as yesterday. None is a top-5 outlet, and none is a feature on injuries, contamination or deaths, which is the forecast's actual quantity. The binding constraint remains the operator rubric logged as a protocol defect on 2026-08-01.

Said plainly so the scorecard agrees: CMS newsroom was not fetched for a second consecutive day, the fetch budget having gone to the two trial primaries and the Federal Register. Today's items are a retail-channel story (Costco's first Medicare partnership, AOL 08-19) and two political-pricing stories — failure case F1 again, since coverage volume is not the forecast quantity. This is a hold on absent information, not on a source checked and found empty. Augur. The one weird thing is inside a primary this run already fetched. `NCT07218445` is a menopause trial, but two of its four primary outcomes are not menopausal at all: plasma cellular-senescence markers, and the gap between epigenetic and chronological age in years. A major academic centre is running an FDA-regulated Phase 4 protocol that formally tests a weight-loss drug as a geroprotective — and it entered through the menopause door, not the longevity one. That is three of Ring 1's five thesis areas fused in one registered protocol, and it is the kind of framing shift that shows up in a trial registry a year before it shows up in the vocabulary.